bioRxiv Science⌕ Search

bioRxiv · 10.1101/2022.08.30.505790

Conjugation of bisphosphonates with scorpion venom enhanced apoptotic activities in pancreatic cancer cells

Abstract

BackgroundIn recent times, prevalence and the incidence of pancreatic cancer (PC) have increased exponentially. Among of the major issues of PC are the asymptotic manifestation that delays diagnosis, and scarcity of therapeutic means. MethodologyTo provide an effective therapeutic approach, current study was executed, in which an optimized alendronate sodium (ALS) and scorpion venom (SV) nanoconjugate (ALS-SV nanoconjugate) was selected via experimental design applying size and zeta potential as the selected factors. Additionally, efficacy against PANC1 cells was determined by analysis of IC50, cell cycle, annexin V staining, Bcl-2, Bax, p53, etc. ResultsThe particle size of the optimized nanoconjugate was found to be 28.4{+/-} 1.2 nm and the zeta potential to be +26.2{+/-} 0.8 mV. The cytotoxicity in terms of IC50 ALS-SV nanoconjugate was found better (2.73 {+/-} 0.2 {micro}g/mL) than ALS alone (22.3 {+/-} 0.2 {micro}g/mL) and SV alone (6.23 {+/-} 0.4 {micro}g/mL). Besides, outcomes of cell cycle analysis exhibited maximum efficacy for nanoconjugate in the G2-M phase. Annexin V staining, Bax, Bcl-2, p53, and caspase 3 estimation also showed superior apoptotic activity for ALS-SV nanoconjugate. However, as compared to ALS alone and SV alone, nanoconjugate showed elevated expression levels of TNF-. The apoptotic activity was enhanced by the ALS-SV nanoconjugate as confirmed by MMP analysis. ConclusionAccordingly, the current study revealed an enhancement in the anti-PC effects of the ALS-SV nanoconjugate that is considered as a novel approach against PC.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Alhakamy, N. A., Al-Rabia, M. W., Rizg, W. Y., Alghaith, A. F., Ahmed, O. A. A., Fahmy, U. A.. 2022-09-03. Conjugation of bisphosphonates with scorpion venom enhanced apoptotic activities in pancreatic cancer cells. https://doi.org/10.1101/2022.08.30.505790

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

Lipid-ASO therapeutics exhibit differential tissue targeted delivery upon systemic or local CNS administration

Antisense oligonucleotides (ASOs) are a powerful therapeutic modality, but their full potential is hindered by pharmacokinetic properties that affect tissue and cellular delivery. Lipid conjugation is increasingly used to modulate ASO's biodistribution and promote extrahepatic activity, yet lipid dependent effects on in vivo functional delivery, particularly in the central nervous system (CNS), remain less explored. Here, we performed a side by side in vivo comparison of cholesterol, palmitic acid (C16:0), docosanoic acid (C22:0), and eicosapentaenoic acid (C20:5) conjugated to a fully phosphorothioated 3 10 3 LNA gapmer ASO targeting the Malat1 long non coding RNA. Lipid-ASO conjugates were administered systemically or locally in the brain of mice and evaluated for tissue level and cellular level distribution by imaging, qPCR and single-cell RNA sequencing, simultaneously annotating cell origin and global transcriptional changes within the cell. Following systemic administration in mice, lipid conjugation improved overall multi organ efficacy compared to unconjugated ASO, but with pronounced tissue specific differences. Single cell sequencing of liver and heart transcriptomes revealed lipid dependent cellular uptake patterns and transcriptional responses distinct from administration of unconjugated ASO. After intracerebroventricular administration, selected fatty acid conjugates enhanced silencing in deep brain regions such as the striatum, whereas cholesterol conjugation impaired functional delivery despite increased CNS retention. Light-sheet microscopy showed restricted parenchymal penetration of cholesterol ASOs compared with broader but heterogeneous distribution of palmitic acid conjugate. Together, these findings demonstrate that lipid identity critically determines ASO efficacy, productive cellular uptake, and regional CNS engagement, emphasizing the need for context specific lipid design in ASO therapeutic development.

pharmacology and toxicology↗

Novel Dissymmetric Ionizable Lipid-Assembled Lipid Nanoparticles for Delivery of Ferroptosis-Related siRNA in Diabetic Treatment

Small interfering RNA (siRNA) enables precise post-transcriptional gene silencing for refractory diseases, yet its clinical translation remains limited by the lack of safe and efficient delivery vectors. Inspired by the dissymmetric alkyl chain architecture of natural membrane phospholipids, we designed and synthesized 34 novel ionizable lipids with dissymmetric hydrophobic tails and formulated them into lipid nanoparticles (LNPs). Through systematic physicochemical and biological assessments, we established clear structure-activity relationships and identified two lead LNPs (O14-LNP, H18a-LNP) with superior endosomal escape capacity, enhanced in vivo gene silencing potency, and favorable biosafety relative to the clinical benchmark MC3-LNP. In both streptozotocin-induced and spontaneous db/db type 2 diabetes (T2D) mouse models, lead LNPs delivering ferroptosis-related siRNAs effectively ameliorated glucose and lipid metabolic disorders, restored islet function, and alleviated hepatic steatosis. This study not only lays a theoretical foundation for the rational design of novel ionizable lipids, but also validates the therapeutic potential of siRNA therapy targeting ferroptosis, providing a versatile delivery platform and targeted therapeutic strategy for the treatment of T2D.

pharmacology and toxicology↗

Oxaliplatin-induced cardiotoxicity in mice is connected to the changes in energy metabolism in the heart tissue

Oxaliplatin is a platinum-based alkylating chemotherapeutic agent used for cancer treatment. At high cumulative dosage, the negative effect of oxaliplatin on the heart becomes evident and is linked to a growing number of clinical reports. The aim of this study was to determine how chronic oxaliplatin treatment causes the changes in energy-related metabolic activity in the heart that leads to cardiotoxicity and heart damage in mice. C57BL/6 male mice were treated with a human equivalent dosage of intraperitoneal oxaliplatin (0 and 10 mg/kg) once a week for eight weeks. During the treatment, mice were followed for physiological parameters, ECG, histology and RNA sequencing of the heart. We identified that oxaliplatin induces strong changes in the heart and affects the hearts energy-related metabolic profile. Histological post-mortem evaluation identified focal myocardial necrosis infiltrated with a small number of associated neutrophils. Accumulated doses of oxaliplatin led to significant changes in gene expression related to energy related metabolic pathways including fatty acid (FA) oxidation, amino acid metabolism, glycolysis, electron transport chain, and NAD synthesis pathway. At high accumulative doses of oxaliplatin, the heart shifts its metabolism from FAs to glycolysis and increases lactate production. It also leads to strong overexpression of genes in NAD synthesis pathways such as Nmrk2. Changes in gene expression associated with energy metabolic pathways can be used to develop diagnostic methods to detect oxaliplatin-induced cardiotoxicity early on as well as therapy to compensate for the energy deficit in the heart to prevent heart damage. Significance StatementThis study uncovers the detrimental impact of chronic oxaliplatin treatment on heart metabolism in mice, linking high accumulative dosages to cardiotoxicity and heart damage. By identifying significant changes in gene expression related to energy metabolic pathways, the findings pave the way for the development of diagnostic methods to detect oxaliplatin-induced cardiotoxicity at an early stage. Furthermore, these insights may inform the creation of therapies that compensate for the energy deficit in the heart, ultimately preventing heart damage and improving patient outcomes in cancer treatment.

pharmacology and toxicology↗